Refractory Ileal Perforations in a Cytomegalovirus-Infected Premature Neonate Resolved After Ganciclovir Therapy
Severe neonatal gastrointestinal diseases such as necrotizing enterocolitis or spontaneous intestinal perforation is a potentially lethal condition that predominantly occurs in premature babies. Cytomegalovirus (CMV), which is known to cause congenital and acquired infections in newborns, has also been implicated in gastrointestinal diseases such as severe in premature infants. However, the pathogenic role of CMV and the effects of antiviral therapy in severe gastrointestinal illness in premature neonates is currently unclear.
We present the baby, born at 26-weeks gestation, presented with progressive dyspepsia and abdominal distention after closure of patent ductus arteriosus symptoms on the day of life (DOL) 4, which requires emergency surgery for ileal perforation in DOL8 it. After surgery, abdominal symptoms persist and operation appeared both performed for recurrent ileal perforation in DOL17. Even after prolonged abdominal symptoms and pathological examination in the affected bowel in a second operation showed CMV inclusion bodies.
Immunoreactivity for CMV antigen was detected in specimens from the first operation on DOL8. Blood and urine CMV-DNA were detected in DOL28. CMV-DNA was also detected in umbilical cord dry obtained within a week of birth. A 6-week course of intravenous ganciclovir (12 mg / kg / day) was started in DOL34 and then the symptoms resolved together with a reduction in CMV-DNA blood. Pathologic findings characteristic of CMV was not detected in the resection specimen in DOL94 ileostomy closure.
These observations suggest that the anti-CMV therapy may be beneficial for some preterm infants with severe gastrointestinal disease related CMV and warrants further research focusing on the role of pathogens, diagnosis, treatment and prevention of this underrecognized etiology severe gastrointestinal disease, especially in premature neonates.
Primary Human Cytomegalovirus Infection and Reactivation: Insights From Molecules Virion-Carried
Human cytomegalovirus (HCMV), a ubiquitous beta-herpes virus, are able to build life-long latency after initial infection. periodic reactivation occurred after immunosuppression, remains a major cause of death in immunocompromised patients. HCMV have to achieve structural balance and functional with the host at the beginning of the entry. virion-do mediators considered to play an important role in the adaptation of the virus into new cellular environment at the time of entry.
Moreover, a clear distinction between primary infection and reactivation is the idea that the virion-packaged factor has been formed so that the molecule can be used quickly by the virus. Instead, the mediator virion-do should be transcribed and translated; thus, they are not available for reactivation. Therefore, understanding the molecular virion-do help to explain HCMV reactivation. In this article, the impact of molecules on the virion-packaged virus structure, biological behavior and life cycle of the virus will be reviewed.
Description: Recombinant human cytomegalovirus pentamer protein complex, consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, produced in HEK293 cells. The gH protein contains a His-tag. This protein has been purified by an additional ion-exchange chromatography step.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Cytomegalovirus Antigen (CMV Ag)
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Cytomegalovirus Antigen (CMV Ag)
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5) Protein pp71 (UL82) Control/blocking peptide
Description: Recombinant human cytomegalovirus pentamer protein complex, consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, produced in HEK293 cells. Contains a His-tag.
Description: Recombinant human cytomegalovirus pentamer protein complex, consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, produced in HEK293 cells. Contains a His-tag.
Description: Recombinant human cytomegalovirus pentamer protein complex, consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, produced in HEK293 cells. Contains a His-tag.
Description: Recombinant gene product from HCMV UL55 locus, amino acid 1-700. A glycine-serine linker and human IgG1 Fc-tag was fused to amino acid 700 of gB. Amino acids 457-460 were replaced with the sequence TTQT to prevent furin cleavage of gB.
Description: Recombinant gene product from HCMV UL55 locus, amino acid 1-700. A glycine-serine linker and human IgG1 Fc-tag was fused to amino acid 700 of gB. Amino acids 457-460 were replaced with the sequence TTQT to prevent furin cleavage of gB.
Cytomegalovirus (CMV) is the most common congenital infection worldwide, and remains a significant cause of neurological deficiencies and sensory deafness in developed countries. Mrs. primary infection, reactivation or reinfection during pregnancy can cause fetal infections and congenital CMV syndrome. The purpose of this study was to analyze the seroprevalence of CMV in accordance with the demographic features of pregnant women in Western Romania as well as the evolution of CMV immunity in two intervals.